Bucharest, Romania – The first implantation of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") in East Europe was recently successfully completed in Emergency Institute for Cardiovascular Diseases "Prof. C. C. Iliescu" in Bucharest, the capital city of Romania. Firehawk® is a target-eluting stent in-house developed by Shanghai MicroPort Medical (Group) Co ("MicroPort®").
The patient is a 48 year-old male with acute myocardial infarction. Professor Adrian Bucsa successfully implanted a Firehawk® stent of 2.75/38 mm in a mid-LAD (left anterior descending coronary artery) of the patient, together with Dr. Marin Postu and Dr. Lucian Zarma. There were no dissections at the stent edges and post-dilation with a 3.0 balloon was easily done. Professor Adrian Bucsa commented that Firehawk® was easily delivered in treating long lesion with good expansion and quick deflation of the balloon, and overall the experience was good in an acute situation.
In the past decade, percutaneous coronary intervention ("PCI") is experiencing rapid development in Romania, with PCI cases increasing year by year from approximately 5,000 cases in 2005 to 15,000 cases in 2014. The successful completion of the first implantation of Firehawk® in East Europe signifies the official entry of the stent in the Romania market and even the East Europe market, to provide ideal treatment solutions to local patients.